In Pt.4 with HLA-I antigens (MFI = 574) and positive for 22% to PD-L1, the capability of CD8+ cells to kill tumor cells was very low (Figure 6B,C,F), whereas the addition of Nivolumab increased it to 38% (Figure 6B,C,G). Here, CD8A is linked to neoplasm.